All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.

  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma Hub
Brought to you by Scientific Education Support

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more
EC approves nivolumab + AVD for cHL
EC approves nivolumab + AVD for cHL
On June 1, 2026, the EC approved nivolumab in combination with doxorubicin + vinblastine + dacarbazine (AVD) for the treatment of patients aged ≥12 years with untreated Stage III or IV classical Hodgkin lymphoma.
Jun 2, 2026|cHL
EC authorizes label expansion for venetoclax combinations in CLL
EC authorizes label expansion for venetoclax combinations in CLL
On May 29, 2026, the EC authorized a label expansion for venetoclax to include its use in combination with acalabrutinib ± obinutuzumab and in com...
Jun 2, 2026|CLL
Annual oncology meeting | Live coverage from the Lymphoma Hub
Annual oncology meeting | Live coverage from the Lymphoma Hub
Catch up with our live social media coverage of lymphoma and CLL from #ASCO26.
May 29, 2026|ASCO 2026
ZUMA-2 phase II 5-year follow-up: Brexu-cel in R/R MCL
ZUMA-2 phase II 5-year follow-up: Brexu-cel in R/R MCL
Five-year follow-up results from the phase II ZUMA-2 trial, evaluating brexu-cel in adults with R/R MCL, were published in the Journal of Hematology & Oncol...
May 29, 2026|MCL
Carousel item
Carousel item
Carousel item
Carousel item
Gilles Salles
Gilles Salles

"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology"

Your opinion matters

What is the primary reason you use bridging therapy in patients with DLBCL awaiting CAR T-cell therapy?

Recent content

VIEW ALL
Australia’s TGA approves orelabrutinib for R/R MCL
Australia’s TGA approves orelabrutinib for R/R MCL
On May 27, 2026, Australia’s Therapeutic Goods Administration (TGA) approved orelabrutinib for the treatment of R/R MCL.
May 28, 2026|MCL
EPCORE NHL-6 phase II interim analysis: Outpatient epcoritamab for 2L+ DLBCL
EPCORE NHL-6 phase II interim analysis: Outpatient epcoritamab for 2L+ DLBCL
Interim results from the phase II EPCORE NHL-6 trial, evaluating the outpatient administration and monitoring of epcoritamab in adults...
May 26, 2026|DLBCL
TAK-007 CAR-NK cell therapy for R/R B-cell NHL: A phase II study
TAK-007 CAR-NK cell therapy for R/R B-cell NHL: A phase II study
Results from a phase II, open-label, multicenter study evaluating TAK-007, a CD19-directed CAR-NK cell therapy, in adults with R/R B-cell NHL, wer...
May 22, 2026|Large B-cell lymphoma
Phase II ELM-2 exploratory analysis: CR dynamics with odronextamab in R/R FL
Phase II ELM-2 exploratory analysis: CR dynamics with odronextamab in R/R FL
Results from an exploratory analysis of the phase II ELM-2 study, evaluating odronextamab in patients with R/R FL, were published in H...
May 20, 2026|FL

Most read

Visual abstract | HD21 final analysis: PET-guided BrECADD vs eBEACOPP in AS cHL
Visual abstract | HD21 final analysis: PET-guided BrECADD vs eBEACOPP in AS cHL
Results from the final analysis of the phase III HD21 trial (NCT02661503) of positron emission tomography (PET)-guided brentuximab ...
Apr 27, 2026|cHL
Phase III BELINDA: tisa-cel vs standard of care as second line treatment of aggressive B-cell lymphoma
Phase III BELINDA: tisa-cel vs standard of care as second line treatment of aggressive B-cell lymphoma
The prognosis for relapsed or refractory aggressive B-cell lymphoma is poor, particularly in those who relap...
Dec 21, 2021
ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL
During the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub was pleased...
Dec 11, 2025|ASH 2025
The 5th edition of the World Health Organization classification of hematolymphoid tumors: lymphoid neoplasms. Part 1
The 5th edition of the World Health Organization classification of hematolymphoid tumors: lymphoid neoplasms. Part 1
This revised 5th edition (WHO-HAEM5) will include a restructuring of entities into a hierarchi...
Nov 17, 2022|aggressive NHL

Lymphoma Hub symposiums

VIEW ALL
Symposium Series | Customizing therapy for MCL
Symposium Series | Customizing therapy for MCL
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Cust...
Sep 12, 2025|ICML 2025
Symposium | Customizing therapy for MCL: Q&A
Symposium | Customizing therapy for MCL: Q&A
The Lymphoma Hub symposium titled ‘Customizing therapy for mantle cell lymphoma’, hosted at the 18th International Conference on Malignant Lymphoma, concluded with a ...
Aug 19, 2025|ICML 2025
Symposium | Current therapies for MCL and their combinations
Symposium | Current therapies for MCL and their combinations
Michael Wang, MD Anderson Cancer Center, Houston, US, presented the third session at the recent Lymphoma Hub symposium, titled ‘Customizing therapy fo...
Aug 8, 2025|ICML 2025
Symposium | Sequencing therapies and practical management of adverse events in MCL
Symposium | Sequencing therapies and practical management of adverse events in MCL
Wojciech Jurczak, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, PL, presented the second session at th...
Jul 25, 2025|ICML 2025

Steering Committee meetings

VIEW ALL
Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial
Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial
During the Lymphoma Hub Steering Committee Meeting on October 6, 2025, key opinion leaders met to discuss the results from the p...
Nov 20, 2025|DLBCL
Anti-CD19 monoclonal antibodies for the treatment of DLBCL
Anti-CD19 monoclonal antibodies for the treatment of DLBCL
During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal an...
Jul 1, 2025|DLBCL
CELMoDs for the treatment of non-Hodgkin lymphoma
CELMoDs for the treatment of non-Hodgkin lymphoma
During the Lymphoma Hub Steering Committee Meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US, chaired a discussion on CELMoDs for the ...
Jun 27, 2025
How to treat MCL that is refractory to BTK inhibitors
How to treat MCL that is refractory to BTK inhibitors
During the Lymphoma Hub Steering Committee meeting, Martin Dreyling, Ludwig-Maximilians-Universität, Munich, DE, chaired a discussion on, How to treat MCL th...
Dec 24, 2024

Drug updates

VIEW ALL
Important announcement
🚨NEWS🚨 @EU_Commission approves nivolumab in combination with AVD for the treatment of patients aged ≥12 years with previously untreated classical Hodgkin lymphoma, based on results from the phase III SWOG 1826 study. Read more: https://bit.ly/4dIoYA9
Jun 2, 2026
Important announcement
🚨NEWS🚨 @EU_Commission authorizes a label expansion for venetoclax to include its use in combination with acalabrutinib ± obinutuzumab and in combination with ibrutinib for the treatment of previously untreated CLL. Read more: https://bit.ly/4dWYSs6
Jun 2, 2026
Important announcement
@US_FDA grants orphan drug designation to EO2463, an off-the-shelf active immunotherapy, for the treatment of indolent NHL in the low-tumor burden, “watch and wait” setting. Read more: https://bit.ly/4wWoWvV
May 28, 2026
Important announcement
🚨NEWS🚨 Australia’s @TGAgovau approves orelabrutinib, a BTK inhibitor, for the treatment of R/R MCL. Read more: https://bit.ly/43xhppV
May 28, 2026